Product Description
Eli Lilly was developing ly-545694, an oral IGLUR5 Inhibitor for Osteoarthritis Knee Pain; an iGluR5 Antagonist. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00790790)
Mechanisms of Action: IGLUR5 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: Eastern America
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Pain Unspecified|Osteoarthritis, Knee
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00785577 |
H8C-MC-LQBF | P2 |
Completed |
Pain Unspecified |
2010-05-01 |
2019-03-18 |
Treatments |
|
NCT00790790 |
H8C-MC-LQBG(a) | P2 |
Completed |
Osteoarthritis, Knee |
2010-01-01 |
2019-03-18 |
Recent News Events
Date |
Type |
Title |
|---|